May 29, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen, CFA
312-265-9574
bsorensen@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Telomir Pharmaceuticals (TELO-NASDAQ)

TELO: Exciting News for AMD Sufferers

Telomir is developing a treatment that has the potential to lead to the extension of human life and solve many age-related health issues. We value TELO at $15.25 using discounted cash flow analysis.

Current Price (05/28/25)	$2.07
Valuation	**$15.25**

OUTLOOK

Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.

The company announced preclinical test results that showed Telomir-1 restored vision and retinal structure in Age-Related Macular Degeneration in an animal model—an encouraging result for millions of AMD sufferers.

SUMMARY DATA

52-Week High	**$7.84**
52-Week Low	**$2.07**
One-Year Return (%)	**-67.81**
Beta	**N/A**
Average Daily Volume (sh)	**135,762**
Shares Outstanding (mil)	**30**
Market Capitalization ($mil)	**$62**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**

Risk Level	**High,**
Type of Stock	**Small-Growth**
Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	0 A	0 A	0 A	0 A	0 A
2024	0 A	0 A	0 A	0 E	0 E
2025	0 A	0 E	0 E	0 E	0 E
2026	0 E	0 E	0.5 E	1.0 E	1.5 E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	-0.45 A
2024	-0.23 A	-0.06 A	-0.20 A	-0.07 A	-0.56 A
2025	-0.07 A	-0.08 E	-0.08 E	-0.08 E	-0.31 E
2026	-0.07 E	-0.07 E	-0.08 E	-0.06 E	-0.28 E

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

UPDATE

Telomir Pharmaceuticals is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA's protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company's primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, "confirms Telomir-1 can reverse biologic aging, extending life while preserving health."

The company continues to expand its potential portfolio and just announced some of the most encouraging test results to date for the approximately 20 million Americans suffering from age-related macular degeneration (AMD) (CDC). Preclinical results from a study evaluating Telomir-1 in a genetically modified zebrafish model of AMD. According to the company, following a 14-day oral dosing regimen, Telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress.

The company detailed the results by noting that the zebrafish showed clear signs of neurodegeneration and visual impairment. Analysis showed that the animals had approximately 15% total retinal degeneration, which affected multiple critical layers.

- The **inner nuclear layer (INL)** was thinned. This layer acts as the retina's central processing zone, where signals from light-sensitive photoreceptors are refined before being passed deeper into the eye.
- The **ganglion cell layer (GCL)** was degraded. This layer contains neurons that form the optic nerve, which sends visual information to the brain. Damage here disrupts vision at its source.
- **The inner plexiform layer (IPL)** volume was reduced. IPL is a retinal layer located between the inner nuclear layer (INL) and the ganglion cell layer (GCL). It may contribute to disease processes through inner retinal changes, inflammation, or vitreoretinal interactions.
- The **outer plexiform layer (OPL)** showed early deterioration. This layer connects photoreceptors to other retinal cells and is essential for detecting changes in light and contrast.

.
After receiving Telomir-1, the company reported that the treated animals showed a substantial recovery, which included structural retinal architecture being restored:

- **Full recovery of INL thickness**, restoring core signal processing in the retina.
- **Improved GCL integrity**, reactivating the transmission of visual information to the brain.
- **Significant augmentation of IPL size,** indicating improved processing of visual signals
- **Improvement of OPL structure**, maintaining input from photoreceptors.

And all of this improvement was the result of a short oral regimen, which would make the treatment easily accessible to millions of patients.

This announcement adds to the portfolio at Telomir and adds to the list of conditions that the company can address. As we've noted before, Telomir-1 has the potential to treat various conditions by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these

underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions.

Lastly, another very important development, the company, announced that it raised $3 million in equity financing through a direct investment and the transaction was very shareholder friendly. There were no warrants, discounts or convertible features involved. This continues this company's outstanding record of raising needed funds in a shareholder friendly way.

It's this extensive experience, stellar management and record of success, combined with the test results we've seen at this stage of the process that makes us excited about the potential for Telomir-1 and Telomir-Ag2 and the company that develops them. We urge investors who have a higher risk tolerance to take a look at TELO and consider investing in a company at an early stage that has a large potential upside, with a low float and positive news flow likely to continue in the near future, providing potential fuel to the stock.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Telomir Pharmaceuticals Income Statement and Balance Sheet							
	2023A	2024A	1Q 2525A	2Q2025E	3Q2025E	4Q2025E	2026E
Revenue	0	0	0	0	0	0	1,500,000
Operating Costs:							
General and Admistrative	(600,192)	(9,636,333)	(1,850,786)	(1,869,294)	(1,887,987)	(1,906,867)	(7,627,467)
Related party travel costs	(1,767,550)	(370,500)	0	0	0	0	0
Research and Development	(1,574,306)	(2,235,341)	(336,996)	(627,434)	(639,983)	(652,782)	(2,611,129)
Total Operating Gain/(Loss)	(3,942,048)	(12,242,174)	(2,187,782)	(2,496,728)	(2,527,969)	(2,559,649)	(8,738,596)
Interest Income/(expenses)	(1,643,049)	(4,290,542)	7,954	15,445	15,599	15,755	63,022
Loss on extingushment of debt	(7,486,767)	0	0	0	0	0	0
Other Income/(Expenses)	-	-	-	-	-	-	-
Net Gain/(Loss)	(13,071,864)	(16,532,716)	(2,179,828)	(2,481,283)	(2,512,370)	(2,543,894)	(8,675,574)
Diluted loss per share	(0.45)	(0.56)	(0.07)	(0.08)	(0.08)	(0.08)	(0.28)
Diluted Wtd Common Shares Outstanding	29,017,857	29,539,219	29,762,671	29,609,814	29,905,912	30,204,971	30,507,021
Assets							
Current Assets							
Cash and cash equivalents	1,231	1,266,131	402,999	3,334,638	2,834,442	2,409,276	2,047,885
Other Assets	433,994	57,874	88,189	207,347	209,420	211,515	213,630
Total Current Assets	435,225	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514
Long Term Assets	4,338,543	-	-	-	-	-	-
Total Assets	4,773,768	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514
Current Liabilities							
Trade accounts payable	707,187	587,536	558,862	506,479	349,471	241,135	166,383
Other Current Liabilities	628,377	93,432	93,432	93,432	94,366	95,310	96,263
Total Current Liabilities	1,335,564	680,968	652,294	599,911	443,837	336,445	262,646
Long-term Liabilities	-	-	-	-	-	-	-
Total Liabilities	1,335,564	680,968	652,294	599,911	443,837	336,445	262,646
Common Stock	-	-	-	-	-	-	-
Additional Paid-in Capital	17,502,346	31,239,895	32,615,580	28,140,559	28,421,965	28,706,184	28,993,246
Accumulated Deficit	(14,064,142)	(30,596,858)	(32,776,686)	(25,198,485)	(25,821,939)	(26,421,838)	(26,994,378)
Total SH deficit/(equity)	3,438,204	643,037	(161,106)	2,942,074	2,600,026	2,284,346	1,998,868
Total Liabilities and SH deficit/(equity)	4,773,768	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.